Pharmacological Inhibition of Chitotriosidase (CHIT1) as a Novel Therapeutic Approach for Sarcoidosis.

Barbara DymekPiotr SklepkiewiczMichal MlackiNazan Cemre GünerPatrycja Nejman-GryzKatarzyna DrzewickaNatalia PrzysuchaAleksandra RymaszewskaMagdalena Paplińska-GorycaAgnieszka ZagozdzonMałgorzata ProboszczŁukasz KrzemińskiJan H von der ThusenKatarzyna GórskaKarolina DzwonekZbigniew ZasłonaPawel DobrzanskiRafał Krenke

Published in: Journal of inflammation research (2022)

In summary, CHIT1 activity was increased in sarcoidosis patients and OATD-01, a first-in-class CHIT1 inhibitor, demonstrated efficacy in murine models of granulomatous inflammation providing a proof-of-concept for its clinical evaluation in sarcoidosis.

Keyphrases

clinical evaluation
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
oxidative stress
prognostic factors
systemic sclerosis